HRMY
Harmony Biosciences Holdings, Inc.
Biotechnology · Healthcare · United States
38.59
close · 2026-10-29
value
90
cheaper than peers90
quality
89
stronger fundamentals89
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 5.51× | 97 |
| price to sales | 2.33× | 89 |
| price to book | 2.24× | 68 |
| EV to EBITDA | 6.83× | 68 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 34.2% | 92 |
| return on equity | 20.5% | 87 |
| revenue growth | 30.3% | 56 |
| debt to equity | 16.0% | 50 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $182.8M |
| employees | 293 |
| first trade | 2020-08-19 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.71 | 2.51 | 2.13 | 2.97 |
| free cash flow | $347.9M | $218.7M | $219.1M | $144.3M |
| net income | $158.7M | $145.5M | $128.9M | $181.5M |
| revenue | $868.5M | $714.7M | $582.0M | $437.9M |
| unusual items | $0 | $0 | -$9.8M | $0 |